

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: NI *et al.*

Application Serial No.: To Be Assigned

Art Unit: To Be Assigned

Filed: Concurrently Herewith

Examiner: To Be Assigned

For: Human Tumor Necrosis Factor  
Receptor TR9

Attorney Docket No.: **PF375P1D1**

**PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.115**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination, Applicants respectfully request entry of the following amendments and remarks. Applicants submit herewith a Version With Markings Showing Changes Made. Please amend the application as follows.

***In the Specification***

Please replace the first full paragraph on Page 1, immediately after the Title and before the heading "Field of the Invention", with the following rewritten paragraph:

-- This application is a divisional of copending U.S. Patent Application Serial No. 09/527,236, filed March 16, 2000, which, in turn, is a continuation-in-part of copending U. S. Application Serial No. 09/095,094, filed June 10, 1998, which, in turn, claims benefit under 35 U.S.C. § 119(e) of the filing date of U.S. Provisional Application Serial No. 60/052,991, filed June 11, 1997, and further claims benefit of priority under 35 U.S.C. § 119(e) of the filing date of U.S. Provisional Application Serial No. 60/126,019, filed on March 24, 1999 and U.S. Provisional Application Serial No. 60/134,220, filed on May 14, 1999; each of which is hereby incorporated by reference in its entirety. --

***In the Drawings***

Please replace the informal drawings of Figures 1A-6 (10 sheets) with the formal drawings of Figures 1A-6 (11 sheets) attached herewith.

***Remarks***


The specification has been amended to update the cross reference to related applications. The drawings have been amended to replace informal drawings of Figures 1A-6 with formal drawings of Figures 1A-6 of the instant application. Thus, no new matter has been added by way of this amendment.

***Conclusion***

Applicants respectfully request that the amendments made above be entered and made of record in the file history of the instant application. If there are any fees due in connection with the filing of this paper, please charge the fees to Deposit Account No. 08-3425.

Respectfully submitted,

Dated: January 10, 2002

  
Jonathan L. Klein (Reg. No. 41,119)  
Attorney for Applicants  
**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 251-6015 (telephone)

JLK/BM/lcc

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: NI *et al.*

Application Serial No.: To Be Assigned

Art Unit: To Be Assigned

Filed: Concurrently Herewith

Examiner: To Be Assigned

For: Human Tumor Necrosis Factor  
Receptor TR9

Attorney Docket No.: PF375P1D1

**Version With Markings To Show Changes Made**

The first complete paragraph on Page 1, immediately after the Title and before the heading "Field of the Invention", has been replaced with the following rewritten paragraph:

--This application is a divisional of copending U.S. Patent Application Serial No. 09/527,236, filed March 16, 2000, which, in turn, is a continuation-in-part of copending U. S. Application Serial No. 09/095,094, filed June 10, 1998, which, in turn, claims benefit under 35 U.S.C. § 119(e) of the filing date of U.S. Provisional Application Serial No. 60/052,991, filed June 11, 1997, and further claims benefit of priority under 35 U.S.C. § 119(e) of the filing date of U.S. Provisional Application Serial No. 60/126,019, filed on March 24, 1999 and U.S. Provisional Application Serial No. 60/134,220, filed on May 14, 1999; each of which is hereby incorporated by reference in its entirety. --